Viewing nowSarvaltaan Tablet 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Seoul Pharmaceutical Co., Ltd.

MFDS item code 200809710 · Notified 2008.09.19 · Insurance code 652902340
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This drug is primarily used to reduce the risk of death in patients with essential hypertension, heart failure intolerant to ACE inhibitors, and stable patients with left ventricular dysfunction after a myocardial infarction. It effectively controls blood pressure to prevent cardiovascular complications and helps alleviate symptoms in heart failure patients. It also significantly contributes to reducing the risk resulting from impaired cardiac function after a myocardial infarction. Therefore, this drug is used to improve cardiovascular health and lower the incidence of related complications.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment In patients with mild to moderate hepatic impairment, it is preferable not to exceed 80 mg per day. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy have not been established in children and adolescents under 18 years of age. The safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this drug. It is also advisable for patients with severe liver dysfunction, liver cirrhosis, or biliary obstruction to avoid using this drug. Patients with hereditary angioedema or those who have previously experienced angioedema with similar medications should not take this drug. Patients with severely impaired renal function or certain kidney diseases should also avoid this drug. Diabetic patients or those with moderate to severe renal impairment should not combine this drug with certain medications. Elderly individuals or patients with high serum potassium levels and mildly impaired liver function should exercise caution when taking this drug. Patients with heart disease or those at risk of a rapid drop in blood pressure should take this medication carefully. Blood pressure may suddenly drop when starting this medication, hence close monitoring is essential, particularly in patients who are dehydrated or low in sodium. This drug may cause side effects such as headache, dizziness, cough, diarrhea, and fatigue, and in rare cases can lead to serious allergic reactions or worsening renal function. Regular monitoring of renal function and potassium levels through blood tests is crucial. This drug can interact with other antihypertensives, diuretics, and anticoagulants, so it is imperative to inform your healthcare provider of any concurrent medications. Particularly, combining with potassium-sparing diuretics or potassium supplements can dangerously elevate serum potassium levels. Pregnant women should not use this drug, and it is also safer to avoid it during breastfeeding. Safety and efficacy in children and adolescents under 18 have not been established. In the elderly, starting at a low dose is necessary to prevent excessively low blood pressure, while closely monitoring their condition. In case of overdose, symptoms may include hypotension, decreased consciousness, and shock, necessitating immediate medical attention for appropriate treatment. This drug should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a well-sealed container to prevent air and moisture ingress. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Oval film-coated tablet of orange color with a grayish tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Seoul Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.